Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant od - neoplazme dojki - endokrini terapija, anti-estrogeni - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. u pre - ili perimenopauzi, u sveobuhvatnoj liječenju s palbociclib treba kombinirati s luteinizirajućeg hormona releasing hormon (lhrh) agonist.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatske neoplazme - endokrinska terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck europe b.v. - follitropin alfa - anovulation; reproductive techniques, assisted; infertility, female; hypogonadism - spolni hormoni i modulatori genitalnog sustava, - Ановуляция (uključujući policističnih jajnika, koncept пбвп) u žena koje ne поддающаяся liječenja klomifen citrat. poticanje razvoja brojnih folikula kod pacijenata koji su na суперовуляции u programima podrške reproduktivnih tehnologija (ВРТ), kao što su in vitro fertilizacije (ivf), гаметы unutar-маточную prijenosa (poklon) i зигот, unutar-маточную prijenosa (ЗИФТ). Гонал-f zajedno s лютенизирующий hormon (lh) je lijek preporuča za poticanje razvoja folikula kod žena s teškim nedostatkom lh i fsh. u kliničkim istraživanjima kod ovih pacijenata su identificirani endogene razina lh u serumu .

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - neoplazme dojki - antineoplastična sredstva - ibrance indiciran za liječenje hormonalnih receptora (op) je pozitivan, людское эпидермическое ako uređaj primatelja 2 faktor rasta (her2 i) negativne lokalno-uobičajena ili metastatskih tumora dojke:u kombinaciji s inhibitor aromataze, u kombinaciji s fulvestrant kod žena koje su dobili preliminarne hormonsko nadomjesno liječenje. u pre - ili perimenopauzi, endokrini terapija mora biti u kombinaciji s luteinizirajućeg hormona releasing hormon (lhrh) agonist.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laronov sindrom - hipofiza i hipotalamusni hormoni i analozi - za dugotrajno liječenje zatajenja rasta u djece i adolescenata s teškim primarne inzulin-kao-rasta-faktor-1 nedostatak (primarni igfd). teška primarne igfd određuje:standardna visina odstupanja rezultat ≤ -3. 0;bazalni inzulin-sličan faktor rasta-1 (igf-1) razine ispod 2. 5. percentile za dob i spol;hormon rasta (gh) adekvatnost;iznimka je sekundarni oblik igf-1 deficit, kao što su гипотрофия, hipotireoza, ili kronični tretman farmakološke doze anti steroida. izražene igfd uključuje bolesnika s mutacije u genu gr receptor (usd), stup-blaženstvo signalnog putu, i igf-1, gen nedostatke; oni ne gh nedovoljan, i tako oni ne mogu odgovoriti adekvatno экзогенным hormon rasta, liječenje. preporučljivo je potvrditi dijagnozu, provode test igf-1 generacija .

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international bv - cstriola - spolni hormoni i modulatori genitalnog sustava - psi - liječenje hormonske ovisne urinarne inkontinencije zbog nesposobnosti mehanizma sfinktera kod ovariohysteerectomiranih kuja.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - olaparib - neoplazme jajnika - antineoplastična sredstva - jajnika cancerlynparza prikazan kao monoterapija za:podržava liječenje odraslih bolesnika s поздними (figo faze iii i iv) u genima brca1/2-mutirani (зародышевой linije i/ili somatskih) brzorezni epitela jajnika, masterbatch cijevi ili primarni перитонеальный rak, koji u odgovor (potpuno ili djelomično) nakon završetka prve linije na bazi platine kemoterapije. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 i 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacijenti moraju prethodno bile tretirane s антрациклина i таксана u (neo)adjuvantne ili метастатический, ako pacijenti nisu prikladni za tih postupaka (vidi odjeljak 5. pacijenti s receptore hormona (h)-pozitivnog raka dojke treba također razvili ili nakon pre-hormonska terapija, ili se smatraju neprikladnim za endokrine terapije. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

recordati rare diseases - pasireotide - acromegaly; pituitary acth hypersecretion - hipofiza i hipotalamusni hormoni i analozi - signifor je indiciran za liječenje odraslih bolesnika s cushingovom bolesti za koje kirurgija nije opcija ili za koga nije uspjela operacija. Сигнифор indiciran za liječenje odraslih bolesnika s akromegalija, za koje je kirurška intervencija nije opcija ili nije bio ljekovito i koji nisu pod kontrolom na liječenje s drugim analog somatostatina.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - follitropin delta - anovulacija - spolni hormoni i modulatori genitalnog sustava, - kontrolirana stimulacija jajnika za razvoj folikula u žena prolazi asistirane reproduktivne tehnologije (art) kao što je oplodnja (ivf) ili intracitoplazmična injekcija spermija (icsi) ciklus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi b.v. - tirotropin alfa - neoplazme štitnjače - prednje hipofize hormoni i analozi, hipofize i гипоталамические hormoni i analozi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.